Replies to post #20416 on Biotech Values

[DewDiligence]

MATK is now down more than 20% today.

I thought the sales guidance for FY06 (ending October) on yesterday’s CC was tepid, but not horrible. If people are selling because the CEO is retiring, I think they’re overestimating his abilities.